

Is Rivaroxaban (Xarelto) in shortage in 2026? Get the latest update on availability, pricing, and what patients can do to find their medication.
If you've been struggling to find Rivaroxaban (brand name Xarelto) at your pharmacy, you're probably wondering: is there an official shortage? The answer is more complicated than a simple yes or no.
Here's what we know as of early 2026 — the facts, not the rumors.
The answer depends on which formulation you need:
But here's the catch: just because tablets aren't on the official shortage list doesn't mean you can easily find them. Many patients report walking into their pharmacy and being told Rivaroxaban is out of stock. The issue is often localized unavailability rather than a nationwide shortage.
Several factors are making it harder to fill Rivaroxaban prescriptions in 2026:
Xarelto was one of the first 10 drugs selected for Medicare Part D price negotiation under the Inflation Reduction Act. The negotiated price of approximately $197 per month took effect in January 2026 — a dramatic reduction from the retail price of $500-$650 per month.
This has been a huge win for Medicare patients, but it has also driven a spike in new prescriptions. More patients can now afford the medication, increasing demand at pharmacies nationwide.
Only the 2.5 mg generic (Rivaroxaban by Lupin and Taro) was approved in March 2025. The 10 mg, 15 mg, and 20 mg strengths — which most patients use — remain brand-name only. Without generic competition at these doses, supply is limited to what Janssen/Bayer manufactures.
Pharmacy chains use automated ordering systems based on historical demand. When demand shifts quickly — as it has with the Medicare price changes — pharmacies may not have ordered enough stock. Independent pharmacies and smaller chains may be similarly affected.
For a deeper look at why this medication is hard to find, read our article: Why is Rivaroxaban so hard to find?
Here's a breakdown of current pricing:
For a complete guide to saving money, read: How to save money on Rivaroxaban in 2026.
There are some positive developments for Rivaroxaban patients this year:
If you're on the 2.5 mg dose (typically for CAD or PAD in combination with Aspirin), you now have a generic option that can save you significant money — as low as $45 per month compared to $500+ for brand-name Xarelto.
The negotiated Medicare price of $197 per month is a game-changer for seniors on Medicare Part D. Combined with the new $2,000 annual out-of-pocket cap, many Medicare patients will pay significantly less for Rivaroxaban than in previous years.
If Rivaroxaban isn't available, several alternatives exist. Generic Apixaban (Eliquis) became available in 2025, and generic Dabigatran (Pradaxa) has been available for several years. These provide more affordable backup options. Learn about all your options in our alternatives to Rivaroxaban guide.
If your local pharmacy doesn't have Rivaroxaban, here's what to do:
For more detailed strategies, read our full guide: How to find Rivaroxaban in stock near you.
The Rivaroxaban situation in 2026 is complicated. Tablets aren't in an official FDA shortage, but many patients are having real trouble finding them. The good news is that pricing is improving (especially for Medicare patients) and generic options are slowly expanding.
Stay proactive. Check availability regularly, plan your refills early, and keep an open line of communication with your doctor. If you need help finding a prescriber, check out our guide on how to find a doctor who prescribes Rivaroxaban near you.
Most importantly, don't stop taking your blood thinner. The risks of going without anticoagulation are too serious. With a little planning and the right tools, you can keep your prescription filled.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.